Ethical Considerations for Oncology Clinical Research
... of care. In some cases, it may actually be worse in efficacy, safety, or both. When participants don’t understand that their care is experimental rather than standard, they can also misunderstand their ability to withdraw from a study (and perhaps receive other available therapies). While research p ...
... of care. In some cases, it may actually be worse in efficacy, safety, or both. When participants don’t understand that their care is experimental rather than standard, they can also misunderstand their ability to withdraw from a study (and perhaps receive other available therapies). While research p ...
Keytruda: a first-in-class cancer therapy
... to receive US regulatory approval. This antibody targets the programmed death-1 (PD-1) pathway – a checkpoint normally involved in preventing tissue damage during chronic inflammation. Keytruda was shown in trials to shrink tumours, sometimes for six months or more, in almost a quarter of patients s ...
... to receive US regulatory approval. This antibody targets the programmed death-1 (PD-1) pathway – a checkpoint normally involved in preventing tissue damage during chronic inflammation. Keytruda was shown in trials to shrink tumours, sometimes for six months or more, in almost a quarter of patients s ...
chapter 15
... 15.5 A variety of other therapies exist, including group therapy, self-help groups, marital or couples therapy and even pet therapy, any of which can involve psychodynamic, cognitive, or behavioral techniques. In group therapy, multiple people meet together regularly, guided by a professional, to w ...
... 15.5 A variety of other therapies exist, including group therapy, self-help groups, marital or couples therapy and even pet therapy, any of which can involve psychodynamic, cognitive, or behavioral techniques. In group therapy, multiple people meet together regularly, guided by a professional, to w ...
Transcranial Magnetic Stimulation for Depression
... energy is calibrated by determining the motor threshold, or the minimum amount of energy necessary to cause the patient's thumb to move when the coil is applied to a brain region called the motor strip. Other treatment parameters that can be changed include the frequency and duration. Even though th ...
... energy is calibrated by determining the motor threshold, or the minimum amount of energy necessary to cause the patient's thumb to move when the coil is applied to a brain region called the motor strip. Other treatment parameters that can be changed include the frequency and duration. Even though th ...
Overview: Macrophage Sodium Channels
... IFN-1b 50 mcg–treated patients) compared with placebo. Baseline variables did not influence the observed treatment effect. Conclusions: There was a significant survival advantage in this cohort of patients receiving early IFN-1b treatment at either dose compared with placebo. Near-complete ascertain ...
... IFN-1b 50 mcg–treated patients) compared with placebo. Baseline variables did not influence the observed treatment effect. Conclusions: There was a significant survival advantage in this cohort of patients receiving early IFN-1b treatment at either dose compared with placebo. Near-complete ascertain ...
Original Research
... Patients: A subset of TBI patients who were initially evaluated by a single physiatrist and who received standard treatments and medications yet had persistent post-concussive symptoms. These patients were then assessed by a single optometrist, and those found to have vertical heterophoria were trea ...
... Patients: A subset of TBI patients who were initially evaluated by a single physiatrist and who received standard treatments and medications yet had persistent post-concussive symptoms. These patients were then assessed by a single optometrist, and those found to have vertical heterophoria were trea ...
Clinical pharmacology of Corticosteroids
... cessation of therapy. The continuing breakdown of protein and diversion of amino acids to glucose increases the need for insulin and over a period of time results in weight gain, fat-deposition, muscle wasting, thinning of the skin with striate and bruising, hyperglycemia, growth retardation (in chi ...
... cessation of therapy. The continuing breakdown of protein and diversion of amino acids to glucose increases the need for insulin and over a period of time results in weight gain, fat-deposition, muscle wasting, thinning of the skin with striate and bruising, hyperglycemia, growth retardation (in chi ...
Figure S1
... boxes have not been diagnosed with HIV and did not adapt their risk behavior. After testing positive for HIV, individuals move to a light grey box with the corresponding disease stage and adapt their behavior. Individuals on treatment (white boxes on bottom) move through three different periods defi ...
... boxes have not been diagnosed with HIV and did not adapt their risk behavior. After testing positive for HIV, individuals move to a light grey box with the corresponding disease stage and adapt their behavior. Individuals on treatment (white boxes on bottom) move through three different periods defi ...
Considerations in Chronic Uveitis Treatment
... regarding outcomes and side effects with respect to these agents? SY: Outcomes and side effects beyond 10 years are still unknown with these agents, however, based on findings from the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) study, which retrospectively looked at whether there was ...
... regarding outcomes and side effects with respect to these agents? SY: Outcomes and side effects beyond 10 years are still unknown with these agents, however, based on findings from the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) study, which retrospectively looked at whether there was ...
Why do some patients benefit from medications while
... determining if the trial results apply to certain patients. They would consider many factors, including the setting of the trial; patient selection and characteristics; and treatment outcomes, including reported adverse drug effects. As a result, they may underuse effective medications. While benefi ...
... determining if the trial results apply to certain patients. They would consider many factors, including the setting of the trial; patient selection and characteristics; and treatment outcomes, including reported adverse drug effects. As a result, they may underuse effective medications. While benefi ...
Dr. Geller NJ WIG Roundtable Presentation
... However in New Jersey, many patients with neurological disorders, and those with other types of chronic health conditions, are currently at risk of losing access to the treatments that are keeping their health stable. Patients are being forced off their medications through a process known as non- ...
... However in New Jersey, many patients with neurological disorders, and those with other types of chronic health conditions, are currently at risk of losing access to the treatments that are keeping their health stable. Patients are being forced off their medications through a process known as non- ...
mesotherapy - Cosmetic Surgery and Wellness
... Mesotherapy requires a series of treatments for larger areas. The number of sessions is determined by the results you desire. Is Mesotherapy safe? Mesotherapy has no serious side effects. All injected substances such as vitamins, antioxidants, phosphatidycholine (a natural soy bean substance) or hya ...
... Mesotherapy requires a series of treatments for larger areas. The number of sessions is determined by the results you desire. Is Mesotherapy safe? Mesotherapy has no serious side effects. All injected substances such as vitamins, antioxidants, phosphatidycholine (a natural soy bean substance) or hya ...
Treatment-Resistant Depression Case 3
... unipolar depression. Citalopram (Celexa) was the initial treatment (20mg daily, titrated to 60mg daily if needed). Three additional levels of treatment were included, based on response. Each treatment level was sustained for at least 12 weeks (if the drug was tolerated) before response was determine ...
... unipolar depression. Citalopram (Celexa) was the initial treatment (20mg daily, titrated to 60mg daily if needed). Three additional levels of treatment were included, based on response. Each treatment level was sustained for at least 12 weeks (if the drug was tolerated) before response was determine ...
73 Post-polio syndrome and amyotrophic lateral sclerosis
... Exlusion of other neurological conditions with similar symptoms. u There are not diagnostic tests or procedures useful to confirm or exclude the diagnosis u ...
... Exlusion of other neurological conditions with similar symptoms. u There are not diagnostic tests or procedures useful to confirm or exclude the diagnosis u ...
TMJ Brochure - OralSurgeryServices.net
... A tender, sore TMJ (joint) is treated by rubbing ice (\water frozen in a Styrofoam cup) over the joint for 20 minutes 3 times per day. (Ice is used over the joint and if muscle problems are predominant heat may be suggested) ...
... A tender, sore TMJ (joint) is treated by rubbing ice (\water frozen in a Styrofoam cup) over the joint for 20 minutes 3 times per day. (Ice is used over the joint and if muscle problems are predominant heat may be suggested) ...
MPM: Malignant Pleural Mesothelioma
... There are a number of factors which influence the decision for the most appropriate treatment. These include the extent to which the disease has spread, the patient’s general health, and the specific type of cancerous cells. Patients will undergo a number of investigations including biopsies and ...
... There are a number of factors which influence the decision for the most appropriate treatment. These include the extent to which the disease has spread, the patient’s general health, and the specific type of cancerous cells. Patients will undergo a number of investigations including biopsies and ...
biologics - Crohn`s and Colitis Foundation of America
... Infections. Because biologics affect the immune system to help control IBD, biologics can impact your ability to fight infections. Further, anti-TNF medications increase the risk of developing less common, or atypical, infections. While the majority of patients using biologics never experience an in ...
... Infections. Because biologics affect the immune system to help control IBD, biologics can impact your ability to fight infections. Further, anti-TNF medications increase the risk of developing less common, or atypical, infections. While the majority of patients using biologics never experience an in ...
Opens New Doors for GI Patients
... approved for use in treating Crohn’s disease in 1998, they are given by intravenous infusion over one to two hours or by injection. Patients often notice an improvement in symptoms within weeks and sometimes days of their treatment. Despite the impressive success in some cases, no drug keeps patient ...
... approved for use in treating Crohn’s disease in 1998, they are given by intravenous infusion over one to two hours or by injection. Patients often notice an improvement in symptoms within weeks and sometimes days of their treatment. Despite the impressive success in some cases, no drug keeps patient ...
Multiple Sclerosis in a Primary Care Setting - Pri-Med
... Dr Regina Berkovich is an assistant professor of Clinical Neurology at the Comprehensive MS Care Center of the Keck School of Medicine, University of Southern California (USC). She has specific training and expertise in Multiple Sclerosis and is one of the key opinion leaders in her field. The USC M ...
... Dr Regina Berkovich is an assistant professor of Clinical Neurology at the Comprehensive MS Care Center of the Keck School of Medicine, University of Southern California (USC). She has specific training and expertise in Multiple Sclerosis and is one of the key opinion leaders in her field. The USC M ...
Management of multiple sclerosis
Several therapies for multiple sclerosis (MS) exist, although there is no known cure. Multiple sclerosis is a chronic inflammatory demyelinating disease that affects the central nervous system (CNS).The most common initial course of the disease is the relapsing-remitting subtype, which is characterized by unpredictable attacks (relapses) followed by periods of relative remission with no new signs of disease activity. After some years, many of the people who have this subtype begin to experience neurologic decline without acute relapses. When this happens it is called secondary progressive multiple sclerosis. Other, less common, courses of the disease are the primary progressive (decline from the beginning without attacks) and the progressive-relapsing (steady neurologic decline and superimposed attacks). Different therapies are used for patients experiencing acute attacks, for patients who have the relapsing-remitting subtype, for patients who have the progressive subtypes, for patients without a diagnosis of MS who have a demyelinating event, and for managing the various consequences of MS.The primary aims of therapy are returning function after an attack, preventing new attacks, and preventing disability. As with any medical treatment, medications used in the management of MS may have several adverse effects, and many possible therapies are still under investigation. At the same time different alternative treatments are pursued by many patients, despite the paucity of supporting, comparable, replicated scientific study.This article focuses on therapies for standard MS; borderline forms of MS have particular treatments that are excluded.